Intrahepatic cholangiocarcinoma: correlation between histological subtype and survival
M. G. Efanov,
N. S. Karnaukhov,
N. N. Britskaia,
N. V. Makarenko,
P. V. Tarakanov,
D. V. Fisenko,
V. V. Tsvirkun https://doi.org/10.16931/1995-5464.2025-1-31-38
Abstract
Aim. To study the pathological histological subtypes of intrahepatic cholangiocarcinoma and their impact on survival.
Materials and methods. The study involved the analysis of perioperative data from 65 patients with intrahepatic cholangiocarcinoma. Among them, 32 patients (49%) were found to have the small bile duct subtype, while 33 patients (51%) were diagnosed with the large bile duct subtype.
Results. The histopathological subtype of intrahepatic cholangiocarcinoma originating from large bile ducts is considered to be a significant factor affecting overall survival (p < 0.0001) and disease-free survival (p =0.0074).
Conclusion. In clinical practice, assessing the small and large duct subtypes of intrahepatic cholangiocarcinoma is claimed to be essential for stratifying risk factors affecting disease prognosis.
About the Authors
M. G. Efanov
Moscow Clinical Scientific Center named after A.S. Loginov
Russian Federation
Russian Federation
Mikhail G. Efanov – Doct. of Sci. (Med.), Head of the Hepatopancreatobiliary Surgery Department, Moscow Clinical Scientific Center named after A.S. Loginov.
86, Sh. Entuziastov, Moscow, 111123
N. S. Karnaukhov
Moscow Clinical Scientific Center named after A.S. Loginov
Russian Federation
Russian Federation
Nikolai S. Karnaukhov – Cand. of Sci. (Med.), Head of the Pathology Department, Moscow Clinical Scientific Center named after A.S. Loginov.
86, Sh. Entuziastov, Moscow, 111123
N. N. Britskaia
Moscow Clinical Scientific Center named after A.S. Loginov
Russian Federation
Russian Federation
Natalia N. Britskaia – Cand. of Sci. (Med.), Doctoral Candidate, Moscow Clinical Scientific Center named after A.S. Loginov.
86, Sh. Entuziastov, Moscow, 111123
N. V. Makarenko
Moscow Clinical Scientific Center named after A.S. Loginov
Russian Federation
Russian Federation
Nadezhda V. Makarenko – Researcher Associate of the Pathology Department, Moscow Clinical Scientific Center named after A.S. Loginov.
86, Sh. Entuziastov, Moscow, 111123
P. V. Tarakanov
Moscow Clinical Scientific Center named after A.S. Loginov
Russian Federation
Russian Federation
Pavel V. Tarakanov – Cand. of Sci. (Med.), Researcher of the Hepatopancreatobiliary Surgery Department, Moscow Clinical Scientific Center named after A.S. Loginov.
86, Sh. Entuziastov, Moscow, 111123
D. V. Fisenko
Moscow Clinical Scientific Center named after A.S. Loginov
Russian Federation
Russian Federation
Denis V. Fisenko – Junior Researcher of the Hepatopancreatobiliary Surgery Department, Moscow Clinical Scientific Center named after A.S. Loginov.
86, Sh. Entuziastov, Moscow, 111123
V. V. Tsvirkun
Moscow Clinical Scientific Center named after A.S. Loginov
Russian Federation
Russian Federation
Victor V. Tsvirkun – Doct. of Sci. (Med.), Professor, Chief Researcher, Moscow Clinical Scientific Center named after A.S. Loginov.
86, Sh. Entuziastov, Moscow, 111123
References
1. Clements O., Eliahoo J., Kim J.U., Taylor-Robinson S.D., Khan S.A. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J. Hepatol. 2020; 72 (1): 95–103. https://doi.org/10.1016/j.jhep.2019.09.007
2. Nakanuma Y., Sato Y., Harada K., Sasaki M., Xu J., Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J. Hepatol. 2010; 2 (12): 419–247. https://doi.org/10.4254/wjh.v2.i12.419
3. Kendall T., Verheij J., Gaudio E., Evert M., Guido M., Goeppert B., Carpino G. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019; 39 Suppl. 1: 7–18. https://doi.org/10.1111/liv.14093
4. Aishima S., Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. J. Hepatobiliary Pancreat. Sci. 2015; 22 (2): 94–100. https://doi.org/10.1002/jhbp.154
5. Liau J.Y., Tsai J.H., Yuan R.H., Chang C.N., Lee H.J., Jeng Y.M. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod. Pathol. 2014; 27 (8): 1163–1173. https://doi.org/10.1038/modpathol.2013.241
6. European Association for the Study of the Liver. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J. Hepatol. 2023; 79 (1): 181–208. https://doi.org/10.1016/j.jhep.2023.03.010
7. Kubo S., Shinkawa H., Asaoka Y., Ioka T., Igaki H., Izumi N., Itoi T., Unno M., Ohtsuka M., Okusaka T., Kadoya M., Kudo M., Kumada T., Kokudo N., Sakamoto M., Sakamoto Y., Sakurai H., Takayama T., Nakashima O., Nagata Y., Hatano E., Harada K., Murakami T., Yamamoto M. Liver Cancer Study Group of Japan Clinical Practice Guidelines for intrahepatic cholangiocarcinoma. Liver Cancer. 2022; 11 (4): 290–314. https://doi.org/10.1159/000522403
8. Vogel A., Bridgewater J., Edeline J., Kelley R.K., Klümpen H.J., Malka D., Primrose J.N., Rimassa L., Stenzinger A., Valle J.W., Ducreux M.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023; 34 (2): 127–140. https://doi.org/10.1016/j.annonc.2022.10.506
9. Abu Hilal M., Aldrighetti L., Dagher I., Edwin B., Troisi R.I., Alikhanov R., Aroori S., Belli G., Besselink M., Briceno J., Gayet B., D'Hondt M., Lesurtel M., Menon K., Lodge P., Rotellar F., Santoyo J., Scatton O., Soubrane O., Sutcliffe R., Van Dam R., White S., Halls M.C., Cipriani F., Van der Poel M., Ciria R., Barkhatov L., Gomez-Luque Y., Ocana-Garcia S., Cook A., Buell J., Clavien P.A., Dervenis C., Fusai G., Geller D., Lang H., Primrose J., Taylor M., Van Gulik T., Wakabayashi G., Asbun H., Cherqui D. The Southampton Consensus Guidelines for laparoscopic liver surgery: from indication to implementation. Ann. Surg. 2018; 268 (1): 11–18. https://doi.org/10.1097/SLA.0000000000002524
10. Breder V.V., Bazin I.S., Balakhnin P.V., Virshke E.R., Kosyrev V.Yu., Ledin E.V., Medvedeva B.M., Moiseenko F.V., Moroz E.A., Petkau V.V., Pokataev I.A. Practical recommendations for the drug treatment of patients with malignant tumors of the liver and biliary system. RUSSCO practical recommendations, part 1. Malignant tumors. 2023; 13 (3s2): 494–538. https://doi.org/10.18027/2224-5057-2023-13-3s2-1-494-538 (In Russian)
11. Hayashi A., Misumi K., Shibahara J., Arita J., Sakamoto Y., Hasegawa K., Kokudo N., Fukayama M. Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma. Am. J. Surg. Pathol. 2016; 40 (8): 1021–1030. https://doi.org/10.1097/PAS.0000000000000670
12. Sigel C.S., Drill E., Zhou Y., Basturk O., Askan G., Pak L.M., Vakiani E., Wang T., Boerner T., Do R.K.G., Simpson A.L., Jarnagin W., Klimstra D.S. Intrahepatic cholangiocarcinomas have histologically and immunophenotypically distinct small and large duct patterns. Am. J. Surg. Pathol. 2018; 42 (10): 1334–1345. https://doi.org/10.1097/PAS.0000000000001118
13. Chung T., Rhee H., Nahm J.H., Jeon Y., Yoo J.E., Kim Y.J., Han D.H., Park Y.N. Clinicopathological characteristics of intrahepatic cholangiocarcinoma according to gross morphologic type: cholangiolocellular differentiation traits and inflammation- and proliferation-phenotypes. HPB (Oxford). 2020; 22 (6): 864–873. https://doi.org/10.1016/j.hpb.2019.10.009
14. Kinzler M.N., Schulze F., Bankov K., Gretser S., Becker N., Leichner R., Stehle A., Abedin N., Trojan J., Zeuzem S., Schnitzbauer A.A., Wild P.J., Walter D. Impact of small duct- and large duct type on survival in patients with intrahepatic cholangiocarcinoma: results from a German tertiary center. Pathol. Res. Pract. 2022; 238: 154126. https://doi.org/10.1016/j.prp.2022.154126
15. Gerber T.S., Müller L., Bartsch F., Gröger L.K., Schindeldecker M., Ridder D.A., Goeppert B., Möhler M., Dueber C., Lang H., Roth W., Kloeckner R., Straub B.K. Integrative analysis of intrahepatic cholangiocarcinoma subtypes for improved patient stratification: clinical, pathological, and radiological considerations. Cancers (Basel). 2022; 14 (13): 3156. https://doi.org/10.3390/cancers14133156
16. Zen Y. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities. Hum. Pathol. 2023; 132: 197–207. https://doi.org/10.1016/j.humpath.2022.06.001
17. Guedj N. Pathology of cholangiocarcinomas. Curr. Oncol. 2022; 30 (1): 370–380. https://doi.org/10.3390/curroncol30010030
18. Banales J.M., Marin J.J.G., Lamarca A., Rodrigues P.M., Khan S.A., Roberts L.R., Cardinale V., Carpino G., Andersen J.B., Braconi C., Calvisi D.F., Perugorria M.J., Fabris L., Boulter L., Macias R.I.R., Gaudio E., Alvaro D., Gradilone S.A., Strazzabosco M., Marzioni M., Coulouarn C., Fouassier L., Raggi C., Invernizzi P., Mertens J.C., Moncsek A., Rizvi S., Heimbach J., Koerkamp B.G., Bruix J., Forner A., Bridgewater J., Valle J.W., Gores G.J. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 2020; 17 (9): 557–588. https://doi.org/10.1038/s41575-020-0310-z
19. Ahn K.S., O'Brien D., Kang Y.N., Mounajjed T., Kim Y.H., Kim T.S., Kocher J.A., Allotey L.K., Borad M.J., Roberts L.R., Kang K.J. Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach. Hepatol. Int. 2019; 13 (4): 490–500. https://doi.org/10.1007/s12072-019-09954-3
20. Ahn K.S., Kang K.J. Molecular heterogeneity in intrahepatic cholangiocarcinoma. World J. Hepatol. 2020; 12 (12): 1148–1157. https://doi.org/10.4254/wjh.v12.i12.1148
21. Andersen J.B., Spee B., Blechacz B.R., Avital I., Komuta M., Barbour A., Conner E.A., Gillen M.C., Roskams T., Roberts L.R., Factor V.M., Thorgeirsson S.S. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012; 142 (4): 1021–1031.e15. https://doi.org/10.1053/j.gastro.2011.12.005
22. Ma B., Meng H., Tian Y., Wang Y., Song T., Zhang T., Wu Q., Cui Y., Li H., Zhang W., Li Q. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma. BMC Cancer. 2020; 20 (1): 318. https://doi.org/10.1186/s12885-020-06804-6
Review
For citations:
Efanov M.G., Karnaukhov N.S., Britskaia N.N., Makarenko N.V., Tarakanov P.V., Fisenko D.V., Tsvirkun V.V. Intrahepatic cholangiocarcinoma: correlation between histological subtype and survival. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery. 2025;30(1):31-38. (In Russ.) https://doi.org/10.16931/1995-5464.2025-1-31-38
Views:
230
Email this article 